Drug Interactions between perindopril and sildenafil
This report displays the potential drug interactions for the following 2 drugs:
- perindopril
- sildenafil
Interactions between your drugs
sildenafil perindopril
Applies to: sildenafil and perindopril
MONITOR: Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications or medications with hypotensive properties, including vasodilators. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation and thus blood pressure (BP) reduction. For example, when sildenafil (100 mg) was coadministered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction in supine BP was 8/7 mmHg. Likewise, in a group of patients whose hypertension was controlled with nifedipine slow-release (30 mg or 60 mg) once daily, the addition of vardenafil (20 mg) produced a mean additional supine BP reduction of 6/5 mmHg compared to placebo. When coadministered with amlodipine (5 mg) daily or enalapril (20 mg) daily, a single dose of avanafil (200 mg) produced a mean maximum decrease in supine systolic BP of 1.2 mmHg (amlodipine) and supine BP of 1.8/3.5 mmHg (enalapril) compared to placebo.
MANAGEMENT: Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents or agents with hypotensive properties. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.
References (3)
- (2001) "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals
- (2003) "Product Information. Levitra (vardenafil)." Bayer
- (2012) "Product Information. Stendra (avanafil)." Vivus LLC.
Drug and food interactions
sildenafil food
Applies to: sildenafil
GENERALLY AVOID: Coadministration with grapefruit juice may slightly increase the oral bioavailability and delay the onset of action of sildenafil. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. In a randomized, crossover study with 24 healthy male volunteers, ingestion of 250 mL of grapefruit juice one hour before and concurrently with a 50 mg dose of sildenafil increased the mean area under the plasma concentration-time curve (AUC) of sildenafil and its pharmacologically active N-desmethyl metabolite by 23% and 24%, respectively, compared to water. Peak plasma concentrations (Cmax) were unaltered, but the time to reach sildenafil Cmax was prolonged by 0.25 hour. The observed increase in sildenafil bioavailability is unlikely to be of clinical significance in most individuals. However, pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability and may be significant in the occasional susceptible patient. Indeed, one subject in the study had a 2.6-fold increase in sildenafil concentrations.
MANAGEMENT: It may be advisable to avoid administration of sildenafil with grapefruit juice to prevent potential toxicity and delay in onset of action.
References (1)
- Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. (2002) "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther, 71, p. 21-29
perindopril food
Applies to: perindopril
GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.
ADJUST DOSING INTERVAL: Administration with food decreased the biotransformation of perindopril to its active metabolite, perindoprilat, resulting in a decrease of perindoprilat bioavailability by 35% and a reduction in the plasma ACE inhibition curve of approximately 20%. When administered as part of a combination product with amlodipine and taken with food, perindopril and perindoprilat absorption rates have decreased by 18% and 14%, respectively, versus fasting. No effect of food on the extent of unmetabolized perindopril absorption has been observed.
MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes. Some authorities recommend administering perindopril before a meal, preferably in the morning. According to the prescribing information, the combination product containing perindopril and amlodipine may be taken with or without food.
References (7)
- Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
- Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20
- (2024) "Product Information. Perindopril Erbumine (perindopril)." Aurobindo Pharma USA Inc
- (2023) "Product Information. Ag-Perindopril (perindopril)." Angita Pharma Inc.
- (2019) "Product Information. Prestalia (amlodipine-perindopril)." Adhera Therapeutics, Inc.
- (2024) "Product Information. Apo-Perindopril/Amlodipine (amlodipine-perindopril)." Apotex Inc
- (2022) "Product Information. Coversyl Plus HD (indapamide-perindopril)." Servier Canada Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.